Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.

PURPOSE/OBJECTIVE(S):After taxane and anthracycline failure, no standard chemotherapy regimen is established in metastatic breast cancer (MBC). Capecitabine and cisplatin (XP) combination shows promising results in gastrointestinal cancer, but there are relatively scarce data in MBC. We reviewed the...

Full description

Bibliographic Details
Main Authors:	Jieun Lee, Hyun Ho Kim, Sang Mi Ro, Ji Hyun Yang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5325186?pdf=render

Similar Items

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
by: Bang Soo-Mee, et al.
Published: (2006-01-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
by: Pin Zhang, et al.
Published: (2016-08-01)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
by: Xiuwen Guan, et al.
Published: (2020-07-01)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
by: Xue-Lian Chen, et al.
Published: (2016-04-01)

CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2010-11-01)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
by: Yang Q, et al.
Published: (2015-09-01)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
by: Ami N Shah, et al.
Published: (2020-06-01)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
by: Salvatore Grisanti, et al.
Published: (2021-02-01)

Role of capecitabine in treating metastatic colorectal cancer in Chinese patients
by: Wang F, et al.
Published: (2014-04-01)

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
by: Sae-Won Han, et al.
Published: (2012-01-01)

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)
by: Tsuburaya Akira, et al.
Published: (2012-07-01)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
by: Thomas Powles, et al.
Published: (2008-09-01)

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
by: Ro Jungsil, et al.
Published: (2012-07-01)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
by: Vito Lorusso, et al.
Published: (2020-01-01)

Neoadjuvant Chemotherapy With Capecitabine Plus Cisplatin in Patients With Locally Advanced Nasopharyngeal Cancer: Case Series Study
by: Reyad Dada, et al.
Published: (2017-10-01)

Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01)

Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer
by: H.A. Alagizy, et al.
Published: (2015-03-01)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
by: Matthew D. Tucker, et al.
Published: (2019-08-01)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
by: Yizhao Xie, et al.
Published: (2021-08-01)

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
by: Lamont Alan, et al.
Published: (2003-07-01)

Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
by: Fangfang Lv, et al.
Published: (2015-01-01)

afe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria
by: Lasgaa Meryem, et al.
Published: (2017-08-01)

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
by: Alba, E., et al.
Published: (2022)

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
by: Nanlin Hu, et al.
Published: (2021-02-01)

Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma
by: Ciprian Tomuleasa, et al.
Published: (2011-04-01)

Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen
by: Lacin S, et al.
Published: (2015-05-01)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
by: Akinaru Yamamoto, et al.
Published: (2020-11-01)

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
by: Anjie Zhu, et al.
Published: (2021-08-01)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
by: Ting Li, et al.
Published: (2015-01-01)

High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
by: A P Seryakov, et al.
Published: (2014-06-01)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience
by: Guo Q, et al.
Published: (2020-02-01)

Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects
by: Ying Gao, et al.
Published: (2021-09-01)

Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance
by: Dong Won Baek, et al.
Published: (2020-07-01)

Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma
by: Kristian Larson, et al.
Published: (2018-01-01)

Capecitabine in the treatment of metastatic colorectal cancer in elderly patients
by: Andrić Zoran, et al.
Published: (2002-01-01)

Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer
by: Raffaele Ardito, et al.
Published: (2018-09-01)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
by: Chilà G, et al.
Published: (2021-06-01)

A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
by: Min Shi, et al.
Published: (2020-03-01)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience [Corrigendum]
by: Guo Q, et al.
Published: (2020-03-01)